218 related articles for article (PubMed ID: 24441646)
1. The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens.
Bornot A; Blackett C; Engkvist O; Murray C; Bendtsen C
J Biomol Screen; 2014 Jun; 19(5):696-706. PubMed ID: 24441646
[TBL] [Abstract][Full Text] [Related]
2. From Phenotypic Hit to Chemical Probe: Chemical Biology Approaches to Elucidate Small Molecule Action in Complex Biological Systems.
Pasquer QTL; Tsakoumagkos IA; Hoogendoorn S
Molecules; 2020 Dec; 25(23):. PubMed ID: 33287212
[TBL] [Abstract][Full Text] [Related]
3. Systematic Identification of Pharmacological Targets from Small-Molecule Phenotypic Screens.
Liu X; Baarsma HA; Thiam CH; Montrone C; Brauner B; Fobo G; Heier JS; Duscha S; Königshoff M; Angeli V; Ruepp A; Campillos M
Cell Chem Biol; 2016 Oct; 23(10):1302-1313. PubMed ID: 27667560
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Prioritization of Tool Compounds for Phenotypic Screening.
Wang Y; Jenkins JL
Methods Mol Biol; 2018; 1787():195-206. PubMed ID: 29736720
[TBL] [Abstract][Full Text] [Related]
5. Target Identification of Compounds from a Cell Viability Phenotypic Screen Using a Bead/Lysate-Based Affinity Capture Platform.
Tang H; Duggan S; Richardson PL; Marin V; Warder SE; McLoughlin SM
J Biomol Screen; 2016 Feb; 21(2):201-11. PubMed ID: 26676096
[TBL] [Abstract][Full Text] [Related]
6. A simple statistical test to infer the causality of target/phenotype correlation from small molecule phenotypic screens.
Wei X; Hoffman AF; Hamilton SM; Xiang Q; He Y; So WV; So SS; Mark D
Bioinformatics; 2012 Feb; 28(3):301-5. PubMed ID: 22155864
[TBL] [Abstract][Full Text] [Related]
7. The evolution of library design: crafting smart compound collections for phenotypic screens.
Spear KL; Brown SP
Drug Discov Today Technol; 2017 Mar; 23():61-67. PubMed ID: 28647087
[TBL] [Abstract][Full Text] [Related]
8. Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery.
Jung HJ; Kwon HJ
Arch Pharm Res; 2015 Sep; 38(9):1627-41. PubMed ID: 26040984
[TBL] [Abstract][Full Text] [Related]
9. Cell perturbation screens for target identification by RNAi.
Demir K; Boutros M
Methods Mol Biol; 2012; 910():1-13. PubMed ID: 22821589
[TBL] [Abstract][Full Text] [Related]
10. A Combination of Screening and Computational Approaches for the Identification of Novel Compounds That Decrease Mast Cell Degranulation.
McShane MP; Friedrichson T; Giner A; Meyenhofer F; Barsacchi R; Bickle M; Zerial M
J Biomol Screen; 2015 Jul; 20(6):720-8. PubMed ID: 25838434
[TBL] [Abstract][Full Text] [Related]
11. Cheminformatics approaches to analyze diversity in compound screening libraries.
Akella LB; DeCaprio D
Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
[TBL] [Abstract][Full Text] [Related]
12. Enrichment analysis for discovering biological associations in phenotypic screens.
Polyakov VR; Moorcroft ND; Drawid A
J Chem Inf Model; 2014 Feb; 54(2):377-86. PubMed ID: 24437550
[TBL] [Abstract][Full Text] [Related]
13. Chemical genetics-based target identification in drug discovery.
Cong F; Cheung AK; Huang SM
Annu Rev Pharmacol Toxicol; 2012; 52():57-78. PubMed ID: 21819237
[TBL] [Abstract][Full Text] [Related]
14. Target deconvolution techniques in modern phenotypic profiling.
Lee J; Bogyo M
Curr Opin Chem Biol; 2013 Feb; 17(1):118-26. PubMed ID: 23337810
[TBL] [Abstract][Full Text] [Related]
15. Target identification of small molecules based on chemical biology approaches.
Futamura Y; Muroi M; Osada H
Mol Biosyst; 2013 May; 9(5):897-914. PubMed ID: 23354001
[TBL] [Abstract][Full Text] [Related]
16. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?
Goldman RC
Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of bioactive small molecule target through phenotypic screening.
Cho YS; Kwon HJ
Bioorg Med Chem; 2012 Mar; 20(6):1922-8. PubMed ID: 22153994
[TBL] [Abstract][Full Text] [Related]
18. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
19. Identifying compound efficacy targets in phenotypic drug discovery.
Schirle M; Jenkins JL
Drug Discov Today; 2016 Jan; 21(1):82-89. PubMed ID: 26272035
[TBL] [Abstract][Full Text] [Related]
20. A natural products approach to drug discovery: probing modes of action of antitumor agents by genome-scale cDNA library screening.
Luesch H; Abreu P
Methods Mol Biol; 2009; 572():261-77. PubMed ID: 20694698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
